Mumbai, Jan 25 (Agency) Pharma major, Lupin Monday said that it has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. Sevelamer Carbonate Tablets had estimated annual sales of USD 348 million in the U.S. (IQVIA MAT September 2020).